Zurück zu Projekte

14032.1;10 PFLS-LS

Development of balanced dual PI3K/mTOR kinase inhibitors: A new generation of potential drugs for targeted cancer therapy (solid tumors)

Zusammenfassung

Development of balanced dual PI3K/mTOR kinase inhibitors: A new generation of potential drugs for targeted cancer therapy (solid tumors)

Weitere Texte

Abstract

The proposed CTI project aims to develop PI3K/mTOR kinase inhibitors as a new generation of drugs for the treatment of solid tumors such as pancreatic cancer. The designed approach allows discovery and development of lipid-modifying enzyme inhibitors. The methodology and the products complement the existing PIQUR technology portfolio, and open a new branch of commercial opportunities. The project is expected to support current PIQUR activities by identifying a best-in-class clinical candidate, which in comparison with the competitor compounds of same mode of action, has a balanced dual PI3K/mTOR inhibition and improved pharmacological properties, providing optimal therapies, tailored to the unique needs of solid tumors.

Beteiligte

Matthias Wymann

Kontaktperson

matthias.wymann@unibas.ch

Universität Basel Matthias Wymann Mattenstrasse 28 4058 Basel BS CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2012-05-31
Enddatum
2014-10-22
Bewilligte Gesamtkosten
CHF 581283.00
Sektion
20 Förderbereich Life Sciences
NABS Politikbereich
Nicht aufteilbare / nicht zuteilbare Forschung

Forschungsdisziplinen

  • P004 Biochemistry, Metabolism 100.0%